Trial Profile
MK-0518B (EU Sourced Lamivudine) Bioequivalence Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 May 2015
Price :
$35
*
At a glance
- Drugs Lamivudine/raltegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 13 May 2015 New trial record